Divi's Laboratories Limited (DIVISLAB) AI Stock Analysis

• Market Cap: ₹1.62T
• Dividend Yield: 0.46%
• Average Volume (3M): 6.36K
• Price to Earnings (P/E): 72.7
• Beta (1Y): 0.86
• Revenue Growth: 16.43%
• EPS Growth: 35.35%
• Country: IN
• Employees: 9,741
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 21.98
• Shares Outstanding: 265,468,570
• 10 Day Avg. Volume: 6,055
• 30 Day Avg. Volume: 6,356
• PEG Ratio: 1.82
• Price to Book (P/B): 9.84
• Price to Sales (P/S): 15.74
• P/FCF Ratio: 290.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 97.57
• Revenue Forecast (FY): ₹106.19B

• Rating: 74 Outperform
• Price Target: ₹6,698.00 ▲(1.44% Upside)
• Action: Upgraded Date: 11/01/25
• Date: Action: Upgraded 11/01/25

Divi's Laboratories Limited has a strong financial foundation with impressive profitability and minimal leverage, which is the most significant factor in its score. The technical analysis indicates strong momentum but warns of potential overbought conditions. The high P/E ratio suggests overvaluation, which is a concern for valuation-focused investors.

Positive Factors

Balance Sheet Strength

Minimal leverage and a strong ROE provide durable financial flexibility. Low debt reduces refinancing and interest risk, allowing the company to fund capacity, quality systems and regulatory compliance internally. This supports long-term supply commitments and resilience through industry cycles.

Profitability & Margins

Sustained high net and operating margins reflect efficient operations and pricing power in API and custom manufacturing. Durable margins underpin reinvestment capacity, support R&D and quality investments, and provide a buffer against cyclical topline swings, aiding long-term cash generation.

Diversified Business Model

A dual model of large-scale generic API sales plus higher-value custom synthesis/CRAMS creates complementary revenue profiles: stable bulk demand and multi-year contract flows. Scale, process-chemistry expertise and repeat customer relationships support durable competitive positioning and revenue visibility.

Negative Factors

Free Cash Flow Volatility

Material volatility in free cash flow, flagged as 'Infinity' for a period, implies inconsistent conversion of accounting profits into cash due to working-capital swings or project timing. This unpredictability can hinder reliable capital allocation, dividend policy and funding of large CDMO investments without external financing.

Slowing Revenue Growth

Recent topline expansion slowed to a 3.1% growth rate, reducing operating leverage benefits of fixed-cost manufacturing. Protracted modest revenue growth complicates scaling higher-margin custom projects and raises pressure to drive margin improvement or secure new multi-year contracts to sustain EPS and cash flow growth.

Gross Margin Compression

A sharp drop in gross margin suggests structural shifts in product mix, pricing pressure or rising input costs. If persistent, this erodes operating and free cash flow margins, weakening the company’s competitive cushion and requiring either higher-value product wins or material cost and yield improvements to restore long-term profitability.

Divi's Laboratories Limited Business Overview & Revenue Model

Company Description

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

How the Company Makes Money

Divi's Laboratories makes money mainly by selling (1) generic APIs and intermediates and (2) custom synthesis/contract development and manufacturing (often referred to as custom manufacturing or CRAMS/CDMO-type work) to pharmaceutical customers. 1) Generic APIs and intermediates: Divi's manufactures APIs used in finished dosage medicines and sells them in bulk to pharmaceutical companies. Revenue is generated from supplying these products at scale, where earnings depend on volumes, product mix (higher-value APIs vs. commoditized ones), pricing dynamics in global API markets, and the company’s ability to manufacture efficiently with strong yields and compliance. 2) Custom synthesis / contract manufacturing: Divi's undertakes contract manufacturing projects for innovator (and other) pharma companies, producing intermediates and APIs according to customer specifications. Revenue is earned through long-term supply arrangements and project-based manufacturing orders, where Divi's is paid for development/scale-up work and/or for manufacturing and supplying contracted molecules. This stream is typically influenced by customers’ commercial lifecycle needs (e.g., launch ramp-ups, steady-state demand) and the company’s execution on quality, regulatory compliance, and delivery. Key factors that support earnings across both streams include regulatory approvals and compliance (enabling supply into regulated markets), manufacturing scale and process chemistry expertise (supporting cost-competitive production), and customer relationships that drive repeat orders and multi-year engagements. Specific material partnerships, customer names, and segment-level revenue splits: null.

Divi's Laboratories Limited Financial Statement Overview

Summary

Divi's Laboratories Limited demonstrates robust financial health with strong profitability, minimal leverage, and efficient operations. The income statement and balance sheet are impressive, but the cash flow statement reveals some volatility in free cash flow growth, which could pose a risk if not managed carefully.

Income Statement

Divi's Laboratories Limited shows strong profitability with a consistent increase in net profit margin from 20.4% to 23.4% over the years. The gross profit margin remains robust, though it has slightly decreased from 66.3% to 34.1% in recent years. Revenue growth is positive at 3.1% for the latest period, indicating a stable upward trajectory. EBIT and EBITDA margins are healthy, reflecting efficient operations.

Balance Sheet

The company maintains an excellent balance sheet with a very low debt-to-equity ratio, indicating minimal leverage risk. Return on equity is strong at 14.6%, showcasing effective use of shareholder funds. The equity ratio is high, suggesting a solid financial structure with significant equity backing the assets.

Cash Flow

Operating cash flow is strong, with a good coverage ratio of 1.34. Free cash flow growth is volatile, showing 'Infinity' due to a significant increase from the previous period, but this may indicate potential instability. The free cash flow to net income ratio is moderate, suggesting room for improvement in converting income to cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	100.29B	93.58B	77.96B	77.49B	87.99B	68.58B
Gross Profit	51.78B	31.91B	45.27B	44.87B	57.07B	45.34B
EBITDA	36.78B	33.21B	25.43B	27.14B	39.97B	29.24B
Net Income	24.85B	21.91B	16.00B	18.24B	29.60B	19.84B
Balance Sheet
Total Assets	181.51B	169.47B	154.70B	144.39B	133.75B	107.74B
Cash, Cash Equivalents and Short-Term Investments	32.61B	37.15B	37.01B	41.36B	27.42B	20.85B
Total Debt	900.00M	40.00M	30.00M	44.90M	36.90M	48.30M
Total Liabilities	27.38B	19.78B	18.99B	16.72B	16.47B	14.79B
Stockholders Equity	154.13B	149.69B	135.71B	127.67B	117.28B	92.95B
Cash Flow
Free Cash Flow	1.01B	5.08B	2.58B	19.86B	11.99B	10.37B
Operating Cash Flow	16.45B	19.46B	12.61B	24.59B	19.12B	19.47B
Investing Cash Flow	-12.61B	-10.99B	-2.69B	-27.07B	-21.95B	751.30M
Financing Cash Flow	-7.20B	-7.97B	-7.99B	-7.97B	-5.32B	-348.90M

Divi's Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6603.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:DIVISLAB, the sentiment is Negative. The current price of 6603.05 is above the 20-day moving average (MA) of 6265.12, above the 50-day MA of 6233.59, and above the 200-day MA of 6365.35, indicating a bearish trend. The MACD of -49.57 indicates Positive momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 26.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:DIVISLAB.

Divi's Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DIVISLAB	74 Outperform	₹1.62T	72.71	―	0.46%	16.43%	35.35%
LUPIN	72 Outperform	₹1.06T	20.49	―	0.57%	15.49%	64.37%
DRREDDY	70 Outperform	₹1.08T	21.88	―	0.63%	14.10%	9.72%
TORNTPHARM	66 Neutral	₹1.44T	51.30	―	0.84%	9.11%	18.76%
LAURUSLABS	66 Neutral	₹532.70B	59.42	―	0.15%	25.83%	421.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SUVEN	43 Neutral	₹31.07B	-9.14	―	―	―	―

Divi's Laboratories Limited Corporate Events

Divi’s Laboratories Opens Special Window for Transfer and Demat of Physical Shares

Divi’s Laboratories has announced the publication of newspaper advertisements regarding the opening of a special window for the transfer and dematerialisation of physical shares, in line with a recent SEBI circular issued on January 30, 2026. The notices, carried in the Financial Express across all editions and in the Hyderabad edition of Andhra Prabha on March 14, 2026, inform shareholders about this regulatory-driven facility, with further details available on the company’s website, signaling continued compliance with evolving securities market norms and easing the transition away from physical share certificates for investors.

Divi’s Laboratories Files SEBI Dematerialisation Compliance Certificate for December Quarter

Divi’s Laboratories Limited has submitted to the National Stock Exchange of India and BSE Limited the quarterly compliance certificate required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by its registrar and share transfer agent KFin Technologies Limited, confirms that all securities received for dematerialisation during the quarter were appropriately processed, either accepted or rejected, duly listed on the recognised stock exchanges, and that physical certificates were mutilated and cancelled with depositories recorded as registered owners within the prescribed 15-day period, underscoring the company’s adherence to regulatory and corporate governance standards in handling its share capital.

Divi’s Laboratories to Close Trading Window Ahead of Q3 FY26 Results

Divi’s Laboratories Limited has announced that it will close its trading window for designated persons, their immediate relatives, and insiders from 1 January 2026 until 48 hours after the company announces its unaudited financial results for the quarter and nine-month period ended 31 December 2025. The move is in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct, reinforcing its governance standards and compliance framework ahead of the upcoming financial disclosure, with the exact board meeting date for approving these results to be communicated later.